Wheezing in Black Preterm Infants: Impact of Vitamin D Supplementation Strategy

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE4

Total Enrollment

300 participants

Study Classification

INTERVENTIONAL

Study Start Date

2013-01-31

Study Completion Date

2017-03-12

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The goal of this study is to identify a vitamin D supplementation strategy that best promotes the lung, immune, and overall health of black infants born preterm (28-36 weeks gestational age). This is a high risk population that seems to have unique vitamin D needs, and inappropriate supplementation may promote wheezing or allergy. The results of this study will help form nutritional recommendations for the approximately 100,000 black infants born at 30-36 weeks gestational age in the U.S. every year.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Respiratory Outcomes After Early Vitamin D Supplementation in Infants Born Extremely Preterm

NCT05615311

Prematurity; Extreme

ACTIVE_NOT_RECRUITING PHASE1/PHASE2

Serum Levels of Vitamin D,Calcium and Magnesium in Preschool Recurrent Wheezers

NCT05040269

Recurrent Wheezes

UNKNOWN

Metabolic Effects of Choline and Docosahexaenoic Acid Supplementation in Preterm Infants

NCT02509728

Infant, Premature

COMPLETED NA

Childhood Allergy and the Neonatal Environment

NCT04215783

Asthma in Children Allergy

ACTIVE_NOT_RECRUITING

Individualized Nutrition to Optimize Preterm Infant Growth and Neurodevelopment

NCT06266455

Very Preterm Maturity of Infant Very Low Birth Weight Infant

RECRUITING NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Black infants face the highest rates of prematurity in the U.S. (18%), have high rates of prematurity-associated wheezing illnesses, and tend to have lower vitamin D levels. The goal of this \[comparative effectiveness\] study is to identify a vit. D supplementation strategy that minimizes recurrent wheezing in infancy. Long recognized as important for bone health, a growing body of evidence suggests that vit. D may play a role in the regulation and development of many organ systems. The D pathway regulates lung inflammation and impacts morphogenesis, structure, and cell growth and survival in bronchial smooth muscle. Vit. D exposure has the potential to skew cytokine expression from a Th1 (less allergic) to a Th2 (more allergic) phenotype. Due to their developmental immaturity, preterm infants may be particularly vulnerable to any positive or negative effects of vit. D supplementation on the lung, airway, and immune system. Our preliminary data, supported by the literature, suggests that overly aggressive vit. D supplementation may inadvertently increase wheezing in infancy in black, but not white, preterm infants; however, vit. D deficiency could theoretically also increase wheezing via vulnerability to respiratory pathogens. The proposed study is a randomized clinical trial comparing the effect of two different enteral vitamin D supplementation strategies on recurrent wheezing in infancy in 300 black infants born preterm at 28 0/7-36 6/7 wks gestational age, a population for whom neither vit. D requirements nor optimal vit. D serum levels have been established. The investigators will test two strategies: (I) sustained supplementation until 6 mo. of age adjusted for prematurity, and (II) cessation of supplementation when a minimum dietary intake of 200 IU/day is reached. The specific aims are to characterize the effect of each strategy on (aim 1) recurrent wheezing and (aim 2) allergic sensitization and atopy. The investigators will (aim 3) explore the relationship between vit. D serum levels and recurrent wheezing. The investigators hypothesize that strategy II will be more effective in promoting pulmonary health by minimizing recurrent wheezing, allergic sensitization, and overall healthcare utilization, and will be sufficient to prevent clinical vit. D deficiency. The investigators also hypothesize that optimal vit. D serum levels will be lower than the norms for other populations.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Wheezing Allergy

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

PREVENTION

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Sustained

Infants will remain on 400 IU/day of cholecalciferol until 6 months of age adjusted for prematurity, regardless of dietary intake

Group Type ACTIVE_COMPARATOR

Cholecalciferol

Intervention Type DRUG

Infants will receive cholecalciferol 400 IU/day PO until they are 6 months of age adjusted for prematurity

Diet-Limited

Infants will receive placebo once their dietary intake of vitamin D has exceeded 200 IU/day

Group Type PLACEBO_COMPARATOR

Cholecalciferol

Intervention Type DIETARY_SUPPLEMENT

Once the dietary intake of vitamin D has exceeded 200 IU/Day, the infants will receive placebo until they are 6 months of age adjusted for prematurity

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Cholecalciferol

Once the dietary intake of vitamin D has exceeded 200 IU/Day, the infants will receive placebo until they are 6 months of age adjusted for prematurity

Intervention Type DIETARY_SUPPLEMENT

Cholecalciferol

Infants will receive cholecalciferol 400 IU/day PO until they are 6 months of age adjusted for prematurity

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

D-Vi-Sol Vitamin D

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. 28 0/7-36 6/7 weeks gestational age (GA) at birth;
2. family identifies the child as black or African American;
3. \< 28 days of supplemental oxygen (subsequent oxygen therapy for \< 72 hrs for a brief subsequent illness or surgery will be allowed);
4. admitted to a participating site NICU, special care nursery, transitional care nursery, or well-baby nursery as a neonate; and
5. \< 40 weeks corrected GA at enrollment.

Exclusion Criteria

1. BPD (\> 28 days of supplemental oxygen);
2. pre-existing diagnosis of moderate to severe osteopenia of prematurity and/or alkaline phosphatase \> 700;
3. history of fracture;
4. gastrointestinal surgery, including for NEC;
5. known gastrointestinal malabsorption;
6. major congenital anomaly;
7. congenital pulmonary or airway disorder (e.g., cystic fibrosis, tracheomalacia, swallowing disorder, bronchopulmonary sequestration);
8. documented wheezing or stridor prior to enrollment;
9. previous vit. D supplementation with \> 400 IU/day;
10. family plans to move more than 60 miles from CWRU or other pre-defined radius at other sites;
11. baseline hypo- or hypercalcemia, hypo- or hyperphosphatemia; and
12. baseline 25(OH) D level \< 10 ng/ml.

Maximum Eligible Age

1 Year

Eligible Sex

ALL

Accepts Healthy Volunteers

No